Makers of Tysabri report the drug has produced positive results in an advanced trial for patients suffering Crohn's disease.
Elan Corp. of Ireland and Biogen Idec Inc. of Massachusetts jointly developed the drug to suppress the symptoms of multiple sclerosis, which attacks the body's central nervous system, and Crohn's, which inflames the gastrointestinal system
